Samsa,
I agree with everything you outlined; the damage these flip-floppers made to the company image I think is more than ever clear over the recent weeks: in fact a positive momentum has been building up, in terms of newsflow regarding the opioid drug landscape (competition issues) and IPCI about to reach paramount catalysts. This usually is what determines the speculative push in biotechs (and not only); but as we know the speculative part in IPCI stock value is simply = to zero.
Tek,
what you mean when you say professional investor ? If you mean professional indipendent traders then I can agree that they can adopt the strategy of trade a price range in order to increase their share count while not adding initial cash.
But when it comes to institutional investors then you may be wrong: they tend to buy and stick with their Investments until major value unlocks.(I can tell you without any doubt and by experience)
Someone trading with 100K usd is not an institutional investor, unless there is an accumulation in tranches going on, but not filp-flopping.
What you say about cash available for the company (and you have been repeating it for quite a while) is correct in absolute terms, but when you look into perspective: AdComm, Purdue lawsuits likely to be settled, political need to find answers to the opioid gigantic issue, competition products starting to being questioned-deeply examined-delayed, etc by the FDA- then you understand that a stock without bad reputation would have likely made a remarkable performance since the beginning of the year(regardless of cash available). I could make you examples, but I know you are well aware of other companies making speculative runs based just on analysts reports, a news article, ...and the like.
that said, it's now IPCI time to deliver and to have some good fate as well.
The price will follow...likely with a bumpy path, but IF Prodras works many of us will have an IPCI T-shirt as their preferred one ! LoL
All JMHO, obvisouly
